Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and Cetuximab in Advanced Anal Carcinoma
NCT03944252Phase 2Unknown
- Sponsor
- Gruppo Oncologico Nord Ovest
- Start
- Sep 2018
- Primary completion
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab, KL-140 in anal squamous cell carcinoma (ASCC), sponsored by Gruppo Oncologico Nord Ovest. Status: unknown.
02
Drugs
avelumabKL-140
03
Conditions
anal squamous cell carcinoma (ASCC)
Beyond the preview
Go deeper on NCT03944252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03944252.